lgenuity, a leader in algal biology and industrial biotechnology, has added Dr. Alex Pudney to the team as Chief Scientific Officer. Dr. Pudney previously worked in both research and start-ups, tackling issues of sustainability and renewable alternatives to petrochemicals. His skills in strain engineering, and expertise in directed evolution and design of experiments, are of particular value to the Algenuity team.
“My background in microbial biotechnology has provided me with a broad and diverse overview of the industry, and I feel very privileged to be joining Algenuity, as I have always held the company in high regard,” he said. “In previous roles, I have benefitted from training in leadership, entrepreneurship and project management that took me beyond simply being technically proficient, and I’m very keen to pass on what I have learned. I enjoy solving problems – from the small detailed intricacies of the lab, to the larger challenges facing the entire industry – and I’m looking forward to working with my new colleagues, who are highly competent and brimming with enthusiasm.
“It’s exciting to be working in an intellectually rigorous setting where you have the freedom and expectation to be creative, and where driving efforts forward will result in innovative tools for algal applications. As CSO, I feel it’s my role to manage the demands of the business and support the staff, helping them to be successful in an environment that brings out the best in people, which ultimately is what will help us achieve our goals in this fast-moving sector.”
“We are delighted to bring Alex on board,” said Dr. Andrew Spicer, CEO of Algenuity, “and look forward to the knowledge and experience he will bring to the team. Algenuity has always prided itself on hiring high calibre scientists, and Alex is no exception to that rule.”
Algenuity’s multidisciplinary team develops proprietary and integrated solutions that increase productivity and performance of algal strains, reduce time to market for algal bioproducts, and boost overall profitability. These enabling technologies include the Algem® labscale photobioreactor, a non-GM directed evolution platform, GM strain engineering platforms, and novel bioprocess development and optimization tools. Algenuity is located in Stewartby, Bedfordshire, within the United Kingdom’s Golden Triangle for biotech between London, Cambridge, and Oxford.